Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002394 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
A NA study of HIV Infections and Candidiasis, Oral, sponsored by Novartis.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT00002394: Completed NA study of HIV Infections and Candidiasis, Oral, sponsored by Novartis.
NCT00002394 is a NA study of HIV Infections and Candidiasis, Oral that has completed, run by Novartis. The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002394, a NA study of HIV Infections and Candidiasis, Oral, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
Conditions Studied
Interventions
- DRUG Terbinafine hydrochloride
Study Locations (9)
Florida
- Therafirst Med Ctr - Fort Lauderdale
- Associates in Research - Fort Myers
- Clireco Inc - Tamarac
- Infectious Diseases Research Inc - Tampa
Illinois
- Northwestern Univ / Division of Infectious Disease - Chicago
New Jersey
- Saint Michaels Med Ctr / Infectious Disease Resch Dpt - Newark
New York
- St Vincents Hosp / Clinical Research Program - New York
Texas
- Univ of Texas Med Branch - Galveston
Virginia
- Hampton Roads Med Specialists - Hampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | NA |
What the finished NCT00002394 record still lists
NCT00002394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Terbinafine hydrochloride is the first listed.
NCT00002394 lists 9 locations in 6 states (Florida, Illinois, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00002394 about?
NCT00002394 is a clinical study titled "Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment". The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
What is the current status of trial NCT00002394?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants.
What conditions does trial NCT00002394 study?
This clinical trial studies the following conditions: HIV Infections, Candidiasis, Oral.
What interventions are being tested in trial NCT00002394?
The interventions under investigation include: Terbinafine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002394?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002394 being conducted?
This trial has 9 study locations across Florida, Illinois, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002394's enrollment target sits among peer trials
30 426th of 542 higher than 102 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer